Pharma Mar traded at 82.85 this Wednesday June 10th, decreasing 0.95 or 1.13 percent since the previous trading session. Looking back, over the last four weeks, Pharma Mar lost 17.40 percent. Over the last 12 months, its price rose by 0.06 percent. Looking ahead, we forecast Pharma Mar to be priced at 93.59 by the end of this quarter and at 86.32 in one year, according to Trading Economics global macro models projections and analysts expectations.
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.